sotagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives	5339	1018899-04-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sotagliflozin zynquista LP-802034 LX4211 LX-4211	Sotagliflozin is a dual inhibitor of sodium glucose cotransporter type 1 (SGLT1) and SGLT2. Local intestinal inhibition of SGLT1, the major transporter for glucose absorption, delays and reduces glucose absorption in the proximal intestine, resulting in a blunting and delay of postprandial hyperglycaemia. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, sotagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion Molecular weight: 424.94 Formula: C21H25ClO5S CLOGP: 3.66 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 79.15 ALOGS: -4.01 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sotagliflozin
zynquista
LP-802034
LX4211
LX-4211

Sotagliflozin is a dual inhibitor of sodium glucose cotransporter type 1 (SGLT1) and SGLT2. Local intestinal inhibition of SGLT1, the major transporter for glucose absorption, delays and reduces glucose absorption in the proximal intestine, resulting in a blunting and delay of postprandial hyperglycaemia. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, sotagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion

Molecular weight: 424.94
Formula: C21H25ClO5S
CLOGP: 3.66
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 79.15
ALOGS: -4.01
ROTB: 6

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 26, 2019	EMA	SANOFI-AVENTIS GROUPE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BK06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D000077203	Sodium-Glucose Transporter 2 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 1	indication	46635009	DOID:9744

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.45	acidic
pKa2	13.37	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium/glucose cotransporter 2	Transporter	P31639	SC5A2_HUMAN	INHIBITOR	IC50	8.75		SCIENTIFIC LITERATURE	DRUG LABEL
Sodium/glucose cotransporter 1	Transporter	P13866	SC5A1_HUMAN	INHIBITOR	IC50	7.44		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
6B4ZBS263Y	UNII
C3502471	UMLSCUI
CHEMBL3039507	ChEMBL_ID
24831714	PUBCHEM_CID
DB12713	DRUGBANK_ID
D10669	KEGG_DRUG
C575681	MESH_SUPPLEMENTAL_RECORD_UI
8312	IUPHAR_LIGAND_ID
9824	INN_ID

Pharmaceutical products:

None